Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 20/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21905697 | 1.00 | GRM2 (0.58) | GRM2 | |
| SCHEMBL16557113 | 0.93 | GRM2 (0.60) | GRM2 | |
| SCHEMBL30136223 | 0.93 | GRM2 (0.60) | GRM2 | |
| SCHEMBL29875869 | 0.93 | GRM2 (0.60) | GRM2 | |
| SCHEMBL16555599 | 0.93 | GRM2 (0.60) | GRM2 | |
| SCHEMBL16557112 | 0.93 | GRM2 (0.60) | GRM2 | |
| Hydrochloric Acid SCHEMBL21905696 | 0.92 | GRM2 (0.59) | GRM2 | |
| Hydrochloric Acid SCHEMBL17889243 | 0.92 | GRM2 (0.59) | GRM2 | |
| SCHEMBL21905694 | 0.91 | GRM2 (0.56) | GRM2 | |
| SCHEMBL17889241 | 0.91 | GRM2 (0.56) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250288584-A1 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2025-09-18 | — | — | US | disclosed |
| US-20250041301-A1 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2025-02-06 | — | — | US | disclosed |
| US-12048696-B2 | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-30 | — | — | US | disclosed |
| CN-109999033-B | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and uses thereof | 詹森药业有限公司 | 2022-12-23 | — | — | CN | disclosed |
| US-11369606-B2 | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use | JANSSEN PHARMACEUTICA NV (BE) | 2022-06-28 | — | — | US | disclosed |
| US-20220143141-A1 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-12 | — | — | US | disclosed |
| US-20220047593-A1 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2022-02-17 | — | — | US | disclosed |
| EP-3827830-A1 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | Janssen Pharmaceutica NV (BE) | 2021-06-02 | — | — | EP | disclosed |
| US-20200138813-A1 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-07 | — | — | US | disclosed |
| US-20200138814-A1 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-07 | — | — | US | disclosed |
| EP-3431106-A1 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | Janssen Pharmaceutica NV (BE) | 2019-01-23 | — | — | EP | disclosed |
| EP-3424535-A1 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | Janssen Pharmaceutica NV (BE) | 2019-01-09 | — | — | EP | disclosed |
| EP-3041839-B1 | 1,2,4-TRIAZOLO[4,3-A]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-26 | — | — | EP | disclosed |
| US-9708315-B2 | 1,2,4-triazolo[4,3-a]pyridine compounds and their use as positive allosteric modulators of MGLUR2 receptors | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-18 | — | — | US | disclosed |
| US-20160367554-A1 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | Neuroadjuvants, Inc | 2016-12-22 | — | — | US | disclosed |
| US-20160194318-A1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12048696-B2 | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use | GRM2, GRIN2A, GRIK2 | GRM2 1/4885 |
| US-20160367554-A1 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | GRM2, GRIN2A, GRIK2 | GRM2 1/4885 |
| US-20250288584-A1 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | GRM2, GRIN2A, GRIK2 | GRM2 1/4885 |
| US-20220047593-A1 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | GRM2, GRIN2A, GRIK2 | GRM2 1/4885 |
| US-20250041301-A1 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | GRM2, GRIN2A, GRIK2 | GRM2 1/4885 |
| US-20160194318-A1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | GRM2, GRM1, GRM3 | GRM2 1/4885 |
| US-20200138813-A1 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | GRM2, GRIN2A, GRIK2 | GRM2 1/4885 |
| US-11369606-B2 | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use | GRM2, GRIN2A, GRIK2 | GRM2 1/4885 |
| US-20200138814-A1 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | GRM2, GRIN2A, GRIK2 | GRM2 1/4885 |
| US-20220143141-A1 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | GRM2, GRIN2A, GRIK2 | GRM2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.